Informações de Ultragenyx Pharmaceutical Inc

Mais detalhes de Ultragenyx Pharmaceutical Inc Empresa

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.



Código da empresaRARE

Nome da EmpresaUltragenyx Pharmaceutical Inc

Data de listagemJan 31, 2014

CEODr. Emil D. Kakkis, M.D., Ph.D.

Número de funcionários1294

Tipo de títulosOrdinary Share

Fim do ano fiscalJan 31

Endereço60 Leveroni Ct

CidadeNOVATO

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal94949

Telefone14154838800

Sitehttps://www.ultragenyx.com/

Código da empresaRARE

Data de listagemJan 31, 2014

CEODr. Emil D. Kakkis, M.D., Ph.D.

Executivos da empresa Ultragenyx Pharmaceutical Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

Dr. Amrit Ray, M.D.

Independent Director

18.02K

+46.74%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

15.69K

-83.00%

Mr. John R. Pinion, II

Chief Quality Officer, Executive Vice President - Translational Sciences

--

Mr. Eric Olson

Chief Business Officer, Executive Vice President

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-1.17%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+41.78%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+83.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+26.57%

Mr. Michael A. Narachi

Independent Director

27.34K

+26.57%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+38.64%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de out

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

Por EmpresaUSD

Nome

Receita

Proporção

Crysvita royalty revenue

85.68M

51.46%

Crysvita

34.73M

20.86%

Dojolvi

23.21M

13.94%

Evkeeza

14.57M

8.75%

Mepsevii

8.31M

4.99%

Por RegiãoUSD

Nome

Receita

Proporção

North America

102.93M

61.82%

Latin America

32.97M

19.80%

Europe

26.40M

15.86%

Japan

4.20M

2.52%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Crysvita royalty revenue

85.68M

51.46%

Crysvita

34.73M

20.86%

Dojolvi

23.21M

13.94%

Evkeeza

14.57M

8.75%

Mepsevii

8.31M

4.99%

Distribuição de ações

Atualizado em: sex, 15 de ago

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

10.58%

BlackRock Institutional Trust Company, N.A.

5.21%

Sands Capital Management, LLC

4.09%

T. Rowe Price Associates, Inc.

2.91%

Baker Bros. Advisors LP

2.88%

Outro

74.34%

Investidores

Proporção

The Vanguard Group, Inc.

10.58%

BlackRock Institutional Trust Company, N.A.

5.21%

Sands Capital Management, LLC

4.09%

T. Rowe Price Associates, Inc.

2.91%

Baker Bros. Advisors LP

2.88%

Outro

74.34%

Tipos de investidores

Investidores

Proporção

Investment Advisor

43.48%

Investment Advisor/Hedge Fund

31.76%

Hedge Fund

20.00%

Individual Investor

3.49%

Research Firm

1.33%

Private Equity

1.31%

Sovereign Wealth Fund

1.02%

Bank and Trust

0.67%

Pension Fund

0.63%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

633

96.87M

100.52%

-1.23M

2025Q2

635

97.48M

101.32%

-2.63M

2025Q1

652

96.83M

102.45%

-3.19M

2024Q4

645

94.29M

102.32%

-4.54M

2024Q3

633

93.51M

101.49%

-6.93M

2024Q2

618

95.17M

101.90%

+3.05M

2024Q1

605

86.17M

101.67%

-4.74M

2023Q4

588

86.44M

105.27%

+5.64M

2023Q3

574

75.90M

106.07%

-3.60M

2023Q2

591

75.05M

105.07%

-3.13M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

10.19M

10.58%

+217.20K

+2.18%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.02M

5.21%

+106.89K

+2.18%

Jun 30, 2025

Sands Capital Management, LLC

3.94M

4.09%

-220.08K

-5.29%

Jun 30, 2025

T. Rowe Price Associates, Inc.

2.80M

2.91%

-334.84K

-10.67%

Jun 30, 2025

Baker Bros. Advisors LP

2.77M

2.88%

+1.20M

+75.92%

Jun 30, 2025

Kakkis (Emil D)

2.69M

2.79%

-31.78K

-1.17%

Mar 07, 2025

JP Morgan Asset Management

2.60M

2.7%

+2.56M

+5502.04%

Jun 30, 2025

State Street Global Advisors (US)

2.57M

2.67%

-46.25K

-1.77%

Jun 30, 2025

Suvretta Capital Management, LLC

2.28M

2.36%

+253.50K

+12.52%

Jun 30, 2025

Fidelity Management & Research Company LLC

2.27M

2.36%

+1.89M

+495.36%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: seg, 6 de out

Nome

Proporção

Motley Fool Small-Cap Growth ETF

3.17%

Global X Genomics & Biotechnology ETF

2.93%

Franklin Genomic Advancements ETF

1.34%

Virtus LifeSci Biotech Products ETF

1.27%

WisdomTree BioRevolution Fund

0.98%

Touchstone Sands Capital US Select Growth ETF

0.8%

SPDR S&P Biotech ETF

0.59%

Goldman Sachs Future Health Care Equity ETF

0.52%

First Trust Multi-Manager Large Growth ETF

0.51%

Putnam Sustainable Future ETF

0.5%

Ver Mais

Motley Fool Small-Cap Growth ETF

Proporção3.17%

Global X Genomics & Biotechnology ETF

Proporção2.93%

Franklin Genomic Advancements ETF

Proporção1.34%

Virtus LifeSci Biotech Products ETF

Proporção1.27%

WisdomTree BioRevolution Fund

Proporção0.98%

Touchstone Sands Capital US Select Growth ETF

Proporção0.8%

SPDR S&P Biotech ETF

Proporção0.59%

Goldman Sachs Future Health Care Equity ETF

Proporção0.52%

First Trust Multi-Manager Large Growth ETF

Proporção0.51%

Putnam Sustainable Future ETF

Proporção0.5%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados